Ann: EFFICACY IN TRANSPLANT REJECTION , page-2

An interesting announcement which may identify a niche for ddrnai if someone like Medistem wanted to take on this program because these other studies clearly show that ddrnai is also useful in both liver and lung transplantation.

I have not seen this niche being filled by any of the other RNAi alternatives.

http://archsurg.ama-assn.org/cgi/content/short/147/4/384?rss=1

"Nonetheless, we believe that recurrent HCV after transplantation remains a problem that may be optimally suited to RNAi. Rather than eradicating established HCV infection, which could conceivably require 100% efficiency in delivery of shRNA hepatocytes, the protection scenario is one in which HCV viral loads are minimal and delivery of shRNAs that is efficient but falls short of 100% may in fact be adequate to inhibit HCV replication while the native host immune system clears the remaining virus. The ability to prevent subsequent graft infection would not only lessen the strain on an already limited organ supply by abrogating the need for readditional transplantation for recurrent HCV but also ultimately be lifesaving to the thousands of patients who would otherwise succumb to this disease. Although the need for new therapies is great, the refinement of the molecular tools by which to develop these therapies may be under way.

http://www.ncbi.nlm.nih.gov/pubmed?term=22503847

Conclusion: Intratracheal administration of p38a shRNA plasmids provided therapeutic effects in a rat model of lung transplantation.